BANK VONTOBEL/PUT/ROCHE GS/200/0.1/20.06.25 Stock

Warrant

DE000VM8KCZ3

Delayed Deutsche Boerse AG 14:01:48 2024-07-05 EDT
0.52 EUR -1.89% Intraday chart for BANK VONTOBEL/PUT/ROCHE GS/200/0.1/20.06.25
Current month+13.04%
1 month-22.39%
Date Price Change
24-07-05 0.52 -1.89%
24-07-04 0.53 +10.42%
24-07-03 0.48 +4.35%
24-07-02 0.46 +6.98%
24-07-01 0.43 -6.52%

Delayed Quote Deutsche Boerse AG

Last update July 05, 2024 at 02:01 pm

More quotes

Static data

Product typeWarrants
Buy / SellPUT
Underlying ROCHE HOLDING AG
IssuerLogo Issuer Vontobel Vontobel
WKN VM8KCZ
ISINDE000VM8KCZ3
Date issued 2024-01-16
Strike 200 CHF
Maturity 2025-06-20 (348 Days)
Parity 10 : 1
Emission price 0.75
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 1.34
Lowest since issue 0.43
Delta-0.17x
Omega 7.992
Premium19.95x
Gearing46.52x
Moneyness 0.8220
Difference Strike -42.95 CHF
Difference Strike %-21.48%
Spread 0.04
Spread %7.14%
Intrinsic value 0.000000

Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
-
More about the company

Ratings for Roche Holding AG

Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings

Consensus: Roche Holding AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
20
Last Close Price
243.3 CHF
Average target price
276.6 CHF
Spread / Average Target
+13.70%
Consensus